

Reminder for women of childbearing potential

- Cipaglucosidase alfa is a type of 'enzyme-replacement therapy' (ERT) that is used in the treatment of late-onset Pompe disease in adults.
- Cipaglucosidase alfa is always used with another medicine called miglustat. It is very important that you read the separate Patient Information Leaflets for both cipaglucosidase alfa and miglustat before starting treatment.
- Cipaglucosidase alfa and miglustat has been prescribed for you only. Do not share this medication with anybody.

Patient Reminder Card for Pombiliti[▼] (cipaglucosidase alfa) + Opfolda (miglustat) for women of childbearing potential

You have been given this card because you have been prescribed cipaglucosidase alfa and miglustat. Please read this card and the package information leaflet thoroughly before starting your treatment with cipaglucosidase alfa and miglustat.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

See www.yellowcard.mhra.gov.uk for how to report side effects. Or search for MHRA Yellow Card in the Google Play or Apple App Store.

NP-AT-UK-00020825 | SEPTEMBER 2025

Important information to know:

- **Pregnancy:** Do not take cipaglucosidase alfa in combination with miglustat if you are pregnant. Be sure to tell your doctor immediately if you become pregnant, think you may be pregnant, or are planning to become pregnant. There may be risks to your unborn child.

- **Breastfeeding:** Cipaglucosidase alfa in combination with miglustat should not be used in women whilst breastfeeding. Be sure to discuss your options with your doctor.

- **Contraception:** Women of childbearing potential must not become pregnant and should maintain reliable contraceptive methods during, and for 4 weeks after, treatment with cipaglucosidase alfa in combination with miglustat.